Division of Experimental Therapeutics, Toronto General Research Institute, University Health Network, Toronto, ON, Canada.
J Gen Virol. 2010 Dec;91(Pt 12):2898-906. doi: 10.1099/vir.0.024323-0. Epub 2010 Aug 25.
The use of ribavirin in influenza treatment is a matter of debate. Due to adamantine- and oseltamivir-resistant strains of the current pandemic H1N1 (pdmH1N1) influenza viruses, the demand for alternative antiviral treatments has increased. This study demonstrated the potent antiviral effects of ribavirin in a mouse model of pdmH1N1 influenza infection (A/Mexico/4108/2009). It was found that treatment with 40 mg ribavirin kg⁻¹ day⁻¹ partially protected the animals if initiated immediately upon infection. Administration of similar concentrations on subsequent days or immediate therapy with lower doses efficiently delayed disease progression. Correlation studies showed a direct relationship between low viral titres in the lung during the early stages of infection with animal survival in ribavirin-treated animals. Reduced lung pathology in animals treated with ribavirin following infection also indicated the importance of immediate treatment. This study revealed the antiviral properties of ribavirin and these results justify comprehensive clinical studies for the use of ribavirin against influenza virus in future outbreaks.
利巴韦林在流感治疗中的应用存在争议。由于当前大流行的 H1N1（pdmH1N1）流感病毒具有金刚烷胺和奥司他韦耐药株，对替代抗病毒治疗的需求增加。本研究在 pdmH1N1 流感感染的小鼠模型中证明了利巴韦林的强大抗病毒作用（A/Mexico/4108/2009）。结果发现，如果在感染后立即开始用 40mg 利巴韦林/kg/天治疗，部分动物可得到保护。在随后的几天给予相同浓度或立即用较低剂量治疗可有效延缓疾病进展。相关性研究表明，在感染早期肺部病毒载量低与利巴韦林治疗动物的存活直接相关。感染后用利巴韦林治疗的动物的肺部病理减少也表明了立即治疗的重要性。本研究揭示了利巴韦林的抗病毒特性，这些结果证明了在未来爆发时全面临床研究利巴韦林对流感病毒的使用是合理的。
